Resource & Biology Controls
Simulating Active
“Death is not the greatest fear of humans; misery is. Death is calm, composed, and mannered. Science may struggle with death, but it can conquer suffering.”
— Immunotherapy Liaison & Palliative Care Perspective
Projected Impact Metrics
Calibrated Synthesis
Quality-Adjusted Life Years (QALYs)
78.4
Net healthy lifespan expectation
Societal Misery Reduction
82.5
Index of mitigated chronic agony
Feasibility Index (100Y)
Moderate (48%)
Therapeutic delivery probability
Dominant Ethical Bottleneck
Equitable access vs radical stratification
Key philosophical obstacle
100-Year Life Extension vs. Misery Attenuation Trajectory
Comparative Projections
100-Year Technological Milestones
Longevity & Palliative Milestones
Year 0 - 25
Senolytics & Targeted Immuno-care
Elimination of senescent toxic cell burden and systemic suppression of intractable chronic oncology pain.
Year 25 - 50
Epigenetic Clock Reprogramming
Yamanaka factor micro-pulsing in vivo to reset cellular methylation markers without teratoma oncogenesis.
Year 50 - 75
Synthetic Transdifferentiation
Adopting *Turritopsis* medusa-to-polyp plasticity into human organ repair, eliminating terminal organ failures.
Year 75 - 100
Universal Neuromodulation
Complete decoupling of mortality transition from physical anguish; elimination of unmanaged human agony.
Evidence models derived from oncology, marine senescence biology, and palliative ethics.